Shawn Kwatra, MD, dermatologist, John Hopkins University, discusses late breaking study results on the long-term efficacy and safety of nemolizumab in patients with prurigo nodularis (PN).
This content was produced independently by The American Journal of Managed Care® and is not endorsed by the American Academy of Dermatology.
Purirgo nodularis (PN) is a chronic skin disorder that is characterized as multiple, firm, flesh to pink colored papules, plaques, and nodules commonly located on the extensor surfaces of the extremities. The lesions are very pruritic and can occur in any age group, according to the NIH.
The study found patients treated with nemolizumab experienced significant improvements in itch, skin lesions, sleep disturbance, and quality of life up to 52 weeks, says Shawn Kwatra, MD, dermatologist, John Hopkins University.
Transcript
Can you provide an overview of the key findings from the interim analysis of the OLYMPIA study regarding the long-term efficacy of nemolizumab in patients with PN?
[In] the nemolizumab long-term extension study, the interim cut that we're seeing today was 52 weeks. And in that 52-week study, we wanted to assess safety and efficacy. Regarding efficacy, 90% of patients achieved a 4-point improvement in their itch. Actually, two thirds of patients were in a relative itch-free state by week 52. There was also very significant improvement in skin lesions. So, 65% to 70% of patients reached an IGA [Investigator Global Assessment] 0 or 1, which denotes clear or almost clear skin by week 52. So significant activity itch, incredible skin findings. And then also, the safety data was consistent with that and earlier phase 3 studies.
What specific measures of efficacy were assessed in the study, and how do the results compare to those observed in previous clinical trials of nemolizumab for patients with PN?
The endpoints that were assess were related to itch, skin lesions, and effects on quality of life and sleep disturbance. And for itch, 90% of patients had a 4-point improvement in their itch, two thirds of patients reaching itch-free state, but it was fast. So, in the group that had never received nemolizumab before, took about 4 weeks for these patients to already have a significant portion of them having a 4-point improvement in their itch. So, that itch relief was very rapid.
There was similarly improved sleep. And so, the metrics for sleep mirrored the metrics of improvement for itch, and then also quality of life was very significantly improved. So, we have this metric for our quality of life index in dermatology, the DLQI [Dermatology Life Quality Index]. And over 50% of patients had a DLQI 0 to 1, which is no impact or minimal impact, and 90% of patients had a 4-point improvement. So, very significant improvement across metrics, itch, skin lesions, sleep disturbance, as well as quality of life.
Dr Kathy Zackowski Discusses the Importance of Rehabilitation Research and Trials in MS
April 26th 2024Kathy Zackowski, PhD, National MS Society, expresses the inherent value of quality rehabilitation trials for broadening clinical understandings of multiple sclerosis (MS) and bettering patient outcomes.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Empowering Community Health Through Wellness and Faith
April 23rd 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In the third episode, Camille Clarke-Smith, EdD, MS, CHES, CPT, discusses approaching community health holistically through spiritual and community engagement.
Listen
Dr Dalia Rotstein: Physicians Must Be Aware MS Affects People of All Backgrounds
April 24th 2024Dalia Rotstein, MD, MPH, emphazises the importance of awareness that multiple sclerosis (MS) impacts patients from various backgrounds as clinicians think through ways to improve access to care and research efforts in MS.
Read More
Dr Kathy Zackowski Discusses the Importance of Rehabilitation Research and Trials in MS
April 26th 2024Kathy Zackowski, PhD, National MS Society, expresses the inherent value of quality rehabilitation trials for broadening clinical understandings of multiple sclerosis (MS) and bettering patient outcomes.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Empowering Community Health Through Wellness and Faith
April 23rd 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In the third episode, Camille Clarke-Smith, EdD, MS, CHES, CPT, discusses approaching community health holistically through spiritual and community engagement.
Listen
Dr Dalia Rotstein: Physicians Must Be Aware MS Affects People of All Backgrounds
April 24th 2024Dalia Rotstein, MD, MPH, emphazises the importance of awareness that multiple sclerosis (MS) impacts patients from various backgrounds as clinicians think through ways to improve access to care and research efforts in MS.
Read More
2 Commerce Drive
Cranbury, NJ 08512